Trials / Completed
CompletedNCT01336686
Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout
A Phase 2 Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of MBX-102 in the Treatment of Hyperuricemia in Patients With Gout
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and effectiveness of MBX-102 compared to placebo when given orally once daily for 4 weeks for the treatment of hyperuricemia in patients with gout.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arhalofenate | Arhalofenate 400 mg once daily for 4 weeks |
| DRUG | Arhalofenate | Arhalofenate 600 mg once daily for 4 weeks |
| DRUG | Placebo comparator | Matching placebo once daily for 4 weeks |
| DRUG | Colchicine | 0.6 mg colchicine daily for flare prophylaxis |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2011-11-01
- Completion
- 2011-11-01
- First posted
- 2011-04-18
- Last updated
- 2015-04-17
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01336686. Inclusion in this directory is not an endorsement.